10-K · April 24, 2026
The 10-K/A adds Part III governance, compensation and related-party disclosures and shows improvement in 2025 operating performance versus 2024 but continued losses and material related‑party activity. Net loss narrowed…
Earnings analysis · 10-Q
XBIO earnings analysis
Filed May 12, 2026 · Our reading of the company's report
The latest report
Xenetic Biosciences, Inc. reported revenue of approximately $806,923 for Q1 2026, indicating a 36% increase from $593,261 in Q1 2025. The net loss for the quarter improved to $(456,382) compared to $(903,141) in the…
Read full summary
Xenetic Biosciences, Inc. reported revenue of approximately $806,923 for Q1 2026, indicating a 36% increase from $593,261 in Q1 2025. The net loss for the quarter improved to $(456,382) compared to $(903,141) in the prior year, resulting in an EPS of $(0.20) versus $(0.59). Management highlights a strategic review process and a necessity for additional capital funding going forward.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.2
What stood out
-
Revenue Up 36% YoY
Revenue increased to $806,923 in Q1 2026 from $593,261 in Q1 2025.
-
Net Loss Narrowed by 49.5%
Net loss improved to $(456,382) compared to $(903,141) for the same quarter last year.
-
EPS Improved Significantly
Diluted EPS improved to $(0.20) from $(0.59) year over year.
-
Lower R&D Expenses
R&D expenses decreased by 24.8% to $661,443 from $879,029 in Q1 2025.
-
Cash Position Remains Strong
Cash balances decreased slightly to $7,347,255 from $7,883,632 at period end.
-
Operating Loss Decrease
Loss from operations was reduced by 46.7%, to $(502,117) from $(942,409) in Q1 2025.
What to watch
-
Need for Future Capital
Management indicated the need for additional capital to support long-term initiatives.
-
Ongoing Strategic Review
Uncertainty regarding the outcomes of the strategic review process could affect operations.
-
Geopolitical Exposure
Management noted potential impacts from geopolitical events on financial conditions.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 4
10-K · March 12, 2026
Xenetic (XBIO) positions itself as an early‑stage immuno‑oncology company focused on advancing a systemic DNase platform toward a first‑in‑human, multicenter, dose‑escalation and dose‑expansion study of IV rhDNase I…
10-Q · May 13, 2025
Xenetic reported Q1 2025 revenue of $593,261, up $82,444 (16.1%) from Q1 2024 revenue of $510,817, and delivered an EPS loss of $(0.59) versus $(0.78) in Q1 2024 (improvement of $0.19). Operating loss remains large:…
10-K · March 18, 2025
Xenetic Biosciences is an early-stage immuno-oncology company focused on advancing a systemic DNase program (IV rhDNase I) toward a first-in-human, multicenter dose-escalation and dose-expansion study in locally…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.